Carrie Liao Sells 2,347 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CAO Carrie Liao sold 2,347 shares of the firm’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $15,818.78. Following the transaction, the chief accounting officer now owns 144,923 shares of the company’s stock, valued at approximately $976,781.02. This represents a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Carrie Liao also recently made the following trade(s):

• On Thursday, December 26th, Carrie Liao sold 2,273 shares of Mind Medicine (MindMed) stock. The stock was sold at an average price of $7.43, for a total transaction of $16,888.39.

Mind Medicine (MindMed) Stock Down 2.9 %

MNMD traded down $0.20 on Wednesday, reaching $6.58. The company’s stock had a trading volume of 1,384,819 shares, compared to its average volume of 1,421,332. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. Mind Medicine has a fifty-two week low of $5.03 and a fifty-two week high of $12.22. The stock has a 50 day moving average of $7.29 and a two-hundred day moving average of $6.96. The company has a market capitalization of $495.92 million, a price-to-earnings ratio of -2.91 and a beta of 2.57.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period in the previous year, the business posted ($0.59) EPS. As a group, analysts forecast that Mind Medicine will post -1.35 EPS for the current fiscal year.

Institutional Trading of Mind Medicine (MindMed)

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in Mind Medicine (MindMed) by 4.7% during the 4th quarter. Wellington Management Group LLP now owns 194,491 shares of the company’s stock worth $1,354,000 after buying an additional 8,769 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Mind Medicine (MindMed) by 32.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,550 shares of the company’s stock valued at $94,000 after acquiring an additional 3,350 shares during the period. AWM Investment Company Inc. grew its position in shares of Mind Medicine (MindMed) by 39.9% during the fourth quarter. AWM Investment Company Inc. now owns 1,193,162 shares of the company’s stock worth $8,304,000 after acquiring an additional 340,162 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Mind Medicine (MindMed) by 20.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 85,044 shares of the company’s stock valued at $592,000 after purchasing an additional 14,691 shares during the last quarter. Finally, Woodline Partners LP boosted its stake in Mind Medicine (MindMed) by 0.3% during the 4th quarter. Woodline Partners LP now owns 1,005,198 shares of the company’s stock worth $6,996,000 after purchasing an additional 2,654 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, March 7th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Chardan Capital began coverage on Mind Medicine (MindMed) in a research note on Friday, December 20th. They set a “buy” rating and a $20.00 target price for the company. Robert W. Baird reduced their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Finally, Evercore ISI initiated coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 price objective for the company. Ten research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Mind Medicine (MindMed) has an average rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.